You are about to leave the Clinical Value website now.

Cancel

Next-Generation Sequencing

7 November 2023

Value and Challenges for Precision Oncology Realisation in Real World Practice

In this interview, Prof Chiu discusses the value of NGS testing to identify lung cancer driver mutations to detect and treat lung cancer early. He also…

READ MORE
23 August 2023

NGS and precision oncology in Australia: insights from Profs Peter Gibbs and Svetlana Cherepanoff

In this article, Prof Peter Gibbs and Prof Svetlana Cherepanoff discuss the issues surrounding the clinical integration of NGS in Australia.

READ MORE
23 August 2023

NGS and precision oncology in Taiwan: insights from Dr Jan-Gowth Chang and Dr Jason CH Hsieh

NGS and digital applications for oncology management can help improve early cancer detection and prevention, reducing human and economic costs of the cancer. In this article,…

READ MORE
18 August 2023

NGS and precision oncology in India: insights from Dr Amit Rauthan

In this article, Dr Amit Rauthan shares insights on the challenges and opportunities for greater NGS adoption in India.

READ MORE
18 August 2023

Clinical and Economic Impact of Upfront Next-Generation Sequencing for Metastatic NSCLC in East Asia

This study aimed to evaluate the economic impact of upfront NGS compared to testing modalities in East Asian patients with mNSCLC, by using Hong Kong as…

READ MORE
17 August 2023

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

This study proposes a unified framework to classify targets for precision cancer medicine based on clinical evidence of utility, to aid oncologists in prioritising potential targets…

READ MORE
11 August 2023

The impact of the multi-disciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumours

The integration of next-generation sequencing (NGS) comprehensive gene profiling (CGP) into clinical practice is playing an increasingly important role in oncology. Therefore, the HKU-HKSH Multi-disciplinary Molecular…

READ MORE

Cancer genomic testing | Jennifer’s story

Comprehensive genomic profiling (CGP) is a method of cancer genomic testing used to reveal the unique set of mutations within the cancer’s DNA which determine how…

READ MORE
22 May 2023

NGS and precision oncology in Hong Kong: insights from Dr Lam Tai-Chung

In this article, Dr Lam Tai-Chung shares how his institution has had first-hand experience of landmark cases and outstanding treatment responses from using NGS in seemingly…

READ MORE
22 May 2023

Next-generation sequencing (NGS) drives precision oncology in Singapore

In this article, Dr David Tan discusses the potential of NGS in Singapore, where the adoption of this technology is only just beginning to take root.

READ MORE
22 May 2023

NGS and precision oncology in South Korea: insights from Prof Kim Jee-Hyun

In this article, Prof Jee Hyun Kim explains her clinical experiences of NGS, and how she sees it evolving within South Korea’s innovative healthcare ecosystem.

READ MORE
22 May 2023

Breaking barriers to precision oncology implementation with digital solutions

While precision oncology has shown great promise, there are still barriers to its implementation, such as data fragmentation, staff shortages and time, funding, and lack of…

READ MORE
19 May 2023

Unlocking the Value of Quality Next-Generation Sequencing in APAC

The advancement of technology has created more opportunities for Next-Generation Sequencing (NGS). With greater public interest in Precision Medicine, it seems hopeful that NGS can potentially…

READ MORE
19 May 2023

National Comprehensive Cancer Network (NCCN) guidelines for lung cancer

The advancement of technology has created more opportunities for Next-Generation Sequencing (NGS). With greater public interest in Precision Medicine, it seems hopeful that NGS can potentially…

READ MORE
19 May 2023

Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group

These recommendations provide a critical guidance from NGS panel testing to final treatment decision based on MTB discussion.

READ MORE

Be the first to receive updates, event opportunities, and thought leadership insights.